Century Therapeutics, Inc. (IPSC)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.49 per share a year ago.
What Makes Century Therapeutics (IPSC) a New Buy Stock
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.55 per share a year ago.
Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.56 per share a year ago.
Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
